The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 11, 2005
Filed:
Apr. 19, 1995
Camille Locht, Wannehain, FR;
Genevieve Renauld, Lyons, FR;
Andre Capron, Phalempin, FR;
Gilles Riveau, Phalempin, FR;
Franco Menozzi, Hyon, BE;
Francoise Jacob-dubuisson, Faches-Thumesnil, FR;
Camille Locht, Wannehain, FR;
Genevieve Renauld, Lyons, FR;
Andre Capron, Phalempin, FR;
Gilles Riveau, Phalempin, FR;
Franco Menozzi, Hyon, BE;
Francoise Jacob-Dubuisson, Faches-Thumesnil, FR;
Institut Pasteur De Lille, Lille Cedex, FR;
Abstract
A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of(Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases ofand is inserted into acell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities ofand particularlyto secrete or surface expose the heterologous polypeptide fused to the Fha portion corresponding to sequence (2), which does not appear to produce extracellular proteases, and the ease with which filamentous haemagglutinins can be isolated from otherproteins.